Please login to the form below

Not currently logged in
Email:
Password:

Haemostatix receives Wellcome Trust Award

Biopharma Haemostatix is to receive a £409,000 Translation Award from the Wellcome Trust to support development of its haemostat technology

Biopharmaceutical company, Haemostatix, is to receive a £409,000 Translation Award from the Wellcome Trust to support development of its innovative haemostat technology, used by surgeons to manage problematic bleeding and to reduce time in the operating theatre during surgery. The products are applied in the form of sprays, gels or pads, and typically contain the enzyme thrombin, which promotes blood clotting, as the active ingredient.

Haemostatix has developed a new class of active ingredient based on a peptide that binds to another blood clotting protein, fibrinogen, instantly forming a clot.

Dr Ben Nichols, CEO of Haemostatix, commented: "There is a real need for rapid acting, ready-to-use haemostats that are safe and cost-effective, and we believe our technology can deliver these benefits to surgeons and their patients. We have received a lot of interest from pharmaceutical companies, and this Award and the investment, will enable us to generate more data to support the commercialisation process."

Dr Richard Seabrook, head of business development at the Wellcome Trust, said: "Bleeding is a major cause of mortality during trauma and control of bleeding during surgery is essential to the outcome of procedures. If successful, a new haemostat that bypasses the need for thrombin has the potential to make a huge impact on healthcare and the Wellcome Trust is pleased to support this project."

The funding coincides with an additional £459,000 investment from Spark Ventures, Catapult Venture Managers, NESTA, the Lachesis Fund and Leicester University, as well as new investor, Mobius Life Sciences Fund.

Haemostatix is based at BioCity Nottingham, Europe's largest bioscience business incubator and was originally a spin-out from Leicester University. Dr Glenn Crocker, CEO of BioCity added: "We have provided Haemostatix with a supportive business development environment for several years and recognise the enormous progress the company has made with its new product. Mobius Life Sciences Fund is designed to contribute to this kind of investment opportunity alongside major investors and we look forward to Haemostatix' further success."

8th November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics